Lukang Pharmaceutical's subsidiary passes generic drug evaluation

Shandong Lukang Pharmaceutical Co., Ltd. (SSE:600789) announced that its holding subsidiary, Shandong Lukang Pharmaceutical Group Cyter Co., Ltd., has received approval from the National Medical Products Administration for its Cimetidine Injection after passing the generic drug quality and efficacy consistency evaluation. Cimetidine Injection, a histamine H2-receptor antagonist used to inhibit gastric acid secretion, can now be marketed as a bioequivalent generic drug. According to the announcement, Cyter Co. has invested approximately CNY 394,850 in research and development related to this consistency evaluation. The company believes this approval will enhance the market competitiveness of the drug and contribute to future generic drug development efforts. However, the company also cautioned investors regarding potential uncertainties related to policy and market conditions.